BIC Announces No Trading in Own Shares for July 2025
ByAinvest
Friday, Aug 1, 2025 11:46 am ET1min read
UTHR--
The repurchase program reflects the company's confidence in its stock's intrinsic value and its ability to generate sustained revenue and cash flow growth. Final settlement for the uncollared ASR is expected in the fourth quarter of 2025, while the collared ASR should settle in the first quarter of 2026. The final number of shares repurchased will be based on the average daily volume-weighted average price during the term of the agreements. United Therapeutics had approximately 45.2 million shares outstanding as of July 30, 2025 [1].
Meanwhile, the broader market has remained relatively flat over the past week, with no significant sector-specific movements. However, over the past year, the market has experienced a 4.8% growth, and earnings are expected to grow by 7.7% per annum over the next few years [2].
In related news, BIC, a global stationery and lighters company, disclosed no transactions in its own shares for July 2025. The company's next financial updates include Q3 2025 net sales on October 28, 2025, and full-year 2025 results on February 24, 2026. BIC has a presence in over 160 countries and a portfolio of iconic brands and products [3].
References:
[1] https://www.investing.com/news/stock-market-news/united-therapeutics-stock-jumps-on-1-billion-share-repurchase-plan-93CH-4165687
[2] https://simplywall.st/stock/tse/3048
[3] https://www.globenewswire.com/news-release/2025/07/30/3124284/0/en/BIC-First-Half-2025-Results.html
BIC, a global stationery and lighters company, disclosed no transactions in its own shares for July 2025. The company's next financial updates include Q3 2025 net sales on October 28, 2025, and full-year 2025 results on February 24, 2026. BIC has a presence in over 160 countries and a portfolio of iconic brands and products.
United Therapeutics Corporation (NASDAQ: UTHR) stock experienced a 4% increase on Friday morning following the announcement of a $1 billion accelerated share repurchase (ASR) program. The company entered into two ASR agreements with Citibank, N.A., totaling $1 billion, with an initial upfront payment of $1 billion on August 4, 2025. The agreements include a $500 million collared and a $500 million uncollared agreement. United Therapeutics will receive approximately 75% of shares under the uncollared agreement and about 50% under the collared agreement [1].The repurchase program reflects the company's confidence in its stock's intrinsic value and its ability to generate sustained revenue and cash flow growth. Final settlement for the uncollared ASR is expected in the fourth quarter of 2025, while the collared ASR should settle in the first quarter of 2026. The final number of shares repurchased will be based on the average daily volume-weighted average price during the term of the agreements. United Therapeutics had approximately 45.2 million shares outstanding as of July 30, 2025 [1].
Meanwhile, the broader market has remained relatively flat over the past week, with no significant sector-specific movements. However, over the past year, the market has experienced a 4.8% growth, and earnings are expected to grow by 7.7% per annum over the next few years [2].
In related news, BIC, a global stationery and lighters company, disclosed no transactions in its own shares for July 2025. The company's next financial updates include Q3 2025 net sales on October 28, 2025, and full-year 2025 results on February 24, 2026. BIC has a presence in over 160 countries and a portfolio of iconic brands and products [3].
References:
[1] https://www.investing.com/news/stock-market-news/united-therapeutics-stock-jumps-on-1-billion-share-repurchase-plan-93CH-4165687
[2] https://simplywall.st/stock/tse/3048
[3] https://www.globenewswire.com/news-release/2025/07/30/3124284/0/en/BIC-First-Half-2025-Results.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet